resolver

Deacon, C.F., Johnsen, A.H., Holst, J.J. (1995). Degradation of glucagon-like
peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a
major endogenous metabolite in vivo. J Clin Endocrinol Metab. 80, 952-957
DeBoer, M.D., Zhu, X.X., Levasseur, .P, Meguid, M.M., Suzuki, S., Inui, A., Taylor,
J.E., Halem, H.A., Dong, J.Z., Datta, R., Culler, M.D., Marks, D.L. (2007). Ghrelin
treatment causes increased food intake and retention of lean body mass in a rat model
of cancer cachexia. Endocrinology 148, 3004-3012
de Weerth, A., Bläker, M., von Schrenck, T. (1999). Receptors for cholecystokinin
and gastrin. Z Gastroenterol. 37, 389-401
Eissele, R., Göke, R., Willemer, S., Harthus, H.P., Vermeer, H., Arnold, R., Göke, B.
(1992). Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat,
pig and man. Eur J Clin Invest. 22, 283-291
Ellrichmann, M., Ritter, P.R., Otte, J.M., Schrader, H., Banasch, M., Brunke, G.,
Herzig, K.H., Seebeck, J., Schmidt, W.E., Schmitz, F. (2007). Orlistat reduces
gallbladder emptying by inhibition of CCK release in response to a test meal. Regul
Pept. 139, 136-140
Ellrichmann, M., Kapelle, M., Ritter, P.R., Holst, J.J., Herzig, K.H., Schmidt, W.E.,
Schmitz, F., Meier, J.J. (2008). Orlistat inhibition of intestinal lipase acutely
increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-
1, cholecystokinin, and peptide YY concentrations. J Clin Endocrinol Metab. 93,
3995-3998
Fehmann, H.C., Göke, R., Göke, B. (1995). Cell and molecular biology of the
incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing
polypeptide. Endocr Rev. 16, 390-410
Flint, A., Raben, A., Astrup, A., Holst, J.J. (1998). Glucagon-like peptide 1 promotes
satiety and suppresses energy intake in humans. J Clin Invest. 101, 515-520
74